Effect of Cardiovascular Risk Factor-Reduction Program Using Transtheoretical Model in Type 2 Diabetes with Metabolic Syndrome

Sunday, November 1, 2009: 3:05 PM

Chun-Ja Kim, RN, PhD1
Dae-Jung Kim, MD2
Hyung-Ran Park1
1Department of Nursing, Ajou University College of Nursing, Suwon, South Korea
2Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea

Learning Objective 1: figure out prevalence of metabolic syndrome in Korean diabetic patients.

Learning Objective 2: figure out the effects of CVD reduction program on metabolic components, HbA1c, depression etc.

Purposes: The purposes of the study were to evaluate a cardiovascular disease (CVD) risk reduction program based on Transtheoretical Model (TTM) in type 2 diabetic participants with metabolic syndrome at a university hospital. Methods: A control group pre- and post- design was used for evaluating the CVD risk reduction program: the intervention group (n=21) participated in the CVD risk reduction program for 24 weeks, while the control group (n=22) received usual educational advice. The cardiovascular risk reduction program based on TTM in type 2 diabetic individuals with metabolic syndrome consisted of goal of program, the assessment tool of stage of change for exercise and weight control, stage-matched program based on results of survey and literature review in detail and glossary. The blood analyses for metabolic cardiovascular syndrome risk factors,  Radloff's CES-D for depression, and TTM's scale were used. The data were analyzed using descriptive statistics, Chi-square test, Students' t-test, repeated measures ANOVA, Cronbach's alpha with SPSS/WIN 12.0. Results: The intervention group, compared to the control group, showed significant improvement in stages of change exercise (t=2.78, p=.008) and reductions in fasting blood sugar(t=-3.07, p=.004), triglyceride(t=-3.09, p=.004), and depression(t=-2.29, p=.027). Conclusions: This study yielded evidence for the beneficial impact of the CVD risk reduction program in type 2 diabetic participants with metabolic syndrome.